Published in AIDS Res Hum Retroviruses on May 01, 2010
Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS (2013) 1.17
FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection. Retrovirology (2012) 0.91
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med (2008) 17.12
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.75
Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr (1992) 2.29
Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol (2000) 2.04
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest (2000) 1.81
Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol (2006) 1.59
Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 1.53
A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology (2003) 1.26
Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.25
Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med (1997) 1.19
Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol (2003) 1.19
Rapid increases in load of human immunodeficiency virus correlate with early disease progression and loss of CD4 cells in vertically infected infants. J Infect Dis (1994) 1.10
Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. J Infect Dis (2000) 0.93
Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J Infect Dis (2001) 0.91
Broadly reactive antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad neutralizing response in human infection. Viral Immunol (1991) 0.82
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med (2012) 1.63
Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol (2006) 1.59
Clinical outcomes after an unstructured treatment interruption in children and adolescents with perinatally acquired HIV infection. Pediatrics (2008) 1.47
Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis (2004) 1.37
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J Virol (2009) 1.34
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J (2003) 1.11
Clearance of Cellulosimicrobium cellulans bacteremia in a child without central venous catheter removal. J Clin Microbiol (2006) 1.09
Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants. J Virol (2002) 0.97
Cellular and humoral immune responses to a tetanus toxoid booster in perinatally HIV-1-infected children and adolescents receiving highly active antiretroviral therapy (HAART). Eur J Pediatr (2006) 0.89
Aureobasidium pullulans var. melanigenum fungemia in a pediatric patient. Med Mycol (2010) 0.87
HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil. Rev Saude Publica (2010) 0.86
Sepsis with prolonged hypotension due to Moraxella osloensis in a non-immunocompromised child. J Med Microbiol (2010) 0.86
Ciprofloxacin-resistant Aeromonas hydrophila cellulitis following leech therapy. J Clin Microbiol (2013) 0.83
Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers. Clin Vaccine Immunol (2010) 0.83
HIV-1 phenotypic drug resistance testing among highly treatment experienced and poorly adherent youth. Pediatr Infect Dis J (2013) 0.83
Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. Pediatr Infect Dis J (2013) 0.81
Outcomes of neonatal candidiasis: the impact of delayed initiation of antifungal therapy. Int J Pediatr (2011) 0.80
Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. J Acquir Immune Defic Syndr (2010) 0.80
Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant Women and Adverse Infant Outcomes. Pediatr Infect Dis J (2016) 0.79
Pneumocephalus and presumed meningitis following inconspicuous penetrating periocular trauma. Acta Ophthalmol Scand (2004) 0.79
Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clin Trials (2009) 0.79
Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy. Pediatr Res (2007) 0.78
The use of linezolid in the treatment of paediatric patients with infections caused by enterococci including strains resistant to vancomycin. J Antimicrob Chemother (2010) 0.76
Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr (2014) 0.76
Interferon-gamma decreases replication of primary R5 HIV-1 isolates in thymocytes. AIDS (2006) 0.76
Modeling vertical transmission of HIV: imperfect vaccines can be of benefit. Vaccine (2009) 0.75
Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies. Int J Clin Pharmacol Ther (2015) 0.75
The changing epidemiology of methicillin-resistant Staphylococcus aureus in pediatric wound cultures: a 10-year experience. Clin Pediatr (Phila) (2012) 0.75
Pharmacokinetics of tenofovir alafenamide with boosted protease inhibitors in pregnant and postpartum women living with HIV: Results from IMPAACT P1026s. J Acquir Immune Defic Syndr (2022) 0.75
Real-time fluorescence polymerase chain reaction (PCR) identification of Streptococcus pneumoniae from pleural fluid and tissue. Scand J Infect Dis (2005) 0.75
Morbidity and Mortality of a Cohort of Peruvian HIV-Infected Children 2003-2012. Pediatr Infect Dis J (2017) 0.75
Herpes Zoster Meningitis Presenting With a Cerebrospinal Fluid Leukemoid Reaction in an Adolescent With preB-ALL in Remission. J Pediatr Hematol Oncol (2016) 0.75